US women experience higher false-positive mammography rates than do European women.
Statistical methods, screening intervals, and mammogram types do not explain the substantial differences in cumulative false-positive risk between the US and Europe, according to a study published in Cancer Epidemiology.
Researchers from Denmark and the United States undertook a study to determine why approximately half of US women have one false-positive test for every 10 screens, while European women have significantly lower rates of false-positives. Screening interval, mammogram type, and statistical methods were evaluated.
The researchers included 99,455 screens from women first screened at age 50 to 69 in the US Breast Cancer Surveillance Consortium (BCSC) between 1996 and 2010, and from two population-based mammography screening programs in Denmark between 1991 and 2012 (230,452 screens) and 1993 to 2013 (400,204 screens).
The researchers found that the empirical cumulative risk of at least one false-positive test after eight (annual or biennial) screens was 41.9% among the women in the BCSC, 16.1% in Copenhagen, and 7.4% in Funen. The researchers noted that the variation in screening interval and mammogram type did not explain the differences by country. Using the Hubbard method, the model-based cumulative risks after eight screens was 45.1% in BCSC, 9.6% in Copenhagen, and 8.8% in Funen. Using the Njor method, these risks were estimated to be 43.6%, 10.9%, and 8.0%.
The study concluded that statistical method, screening interval, and mammogram type does not explain the differences in occurrence of cumulative false-positive risk between the United States and Europe.
ECR Mammography Study: Pre-Op CEM Detects 34 Percent More Multifocal Masses than Mammography
February 28th 2025In addition to contrast-enhanced mammography (CEM) demonstrating over a 90 percent detection rate for multifocal masses, researchers found that no significant difference between histological measurements and CEM, according to study findings presented at the European Congress of Radiology.
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.